title: [Efficacy of movalis in the treatment of acute low back pains].
abstract: The main aim of the study was a search for factors influencing efficacy of movalis used in combined form, injection and tablets, for the treatment of patients with acute back pain syndrome (BPS) and evaluation of the drug safety. Thirty patients, 18 female, 12 male, mean age 43.1 years, with primary BPS have been studied. In 83% of patients, BPS was caused by muscle tonic syndrome and in 17% the latter was combined with radiculopathy. Meloxicam therapy was conducted using intramuscular injections of 15 mg daily during 5 days with following oral drug intake (1 tablet daily). Treatment duration was 2 weeks. This treatment regime proved to be highly effective. The subjective meloxicam efficacy was the following: moderate--7%; good--30%; very good--33%; excellent--30%. Side effects, such as transient stomach pain, was observed only in 6.6% of patients. The main factors reducing meloxicam efficacy were affective disorders, namely, a level of depression and anxiety, and radiculopathy.
authors.forename: E G
authors.initials: EG
authors.lastname: Filatova
authors.forename: A V
authors.initials: AV
authors.lastname: Kondrikov
authors.forename: O I
authors.initials: OI
authors.lastname: Istomina
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D001007:Anxiety / Q000175:diagnosis / Q000453:epidemiology; D003863:Depression / Q000175:diagnosis / Q000453:epidemiology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D017116:Low Back Pain / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D000077239:Meloxicam; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000503:physiopathology; D011584:Psychology; D011843:Radiculopathy / Q000453:epidemiology / Q000503:physiopathology; D011795:Surveys and Questionnaires; D013843:Thiazines / Q000008:administration & dosage / Q000627:therapeutic use*; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam